Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009722 | 0.86 | MBOAT4 (0.38) | IRAK4ADORA2ASYKKCNH2MAPK3 | |
| SCHEMBL5410869 | 0.72 | ADORA2A (0.62) | ADORA2AMAPK1ADORA3ADORA1ADORA2B | |
| SCHEMBL5651588 | 0.72 | ADORA2A (0.56) | ADORA2AADORA1 | |
| SCHEMBL5407687 | 0.72 | ADORA2A (0.42) | ADORA2A | |
| SCHEMBL5653328 | 0.71 | ADORA2A (0.46) | ADORA2AMAPK1ADORA3ADORA1ADORA2B | |
| SCHEMBL5095982 | 0.68 | ADORA2A (0.47) | ADORA2A | |
| SCHEMBL23998430 | 0.62 | IRAK4 (0.39) | IRAK4ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL23998433 | 0.62 | IRAK4 (0.39) | IRAK4ADORA2AADORA3ADORA1ADORA2B | |
| Hydrochloric Acid SCHEMBL30250964 | 0.62 | IRAK4 (0.38) | IRAK4ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL15575979 | 0.61 | IDO1 (0.43) | IRAK4SYKKCNH2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1618109-A2 | TRIAZOLO[1,5-C]PYRIMIDINES AND PYRAZOLO[1,5-C]PYRIMIDINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004092172-A2 | TRIAZOLO[1,5-C]PYRIMIDINES AND PYRAZOLO[1,5-C]PYRIMIDINES USEFUL AS A2A ADENOSIN E RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010522-A1 | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists | ADORA2A, ADORA3, ADORA1 | IRAK4 1631/4885ADORA2A 1/4885SYK 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.